Condition: Adult Growth Hormone Deficiency · Sponsor: Xiamen Amoytop Biotech Co., Ltd.
This is a multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled phase Ⅱa clinical trial. A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose cohorts, and within each dose cohort, participants will be randomized in a 3:1 ratio.
This description comes directly from the study's public registry record.
Yiming Li, Ph.D · 13501936597 · yimingli@fudan.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, China | Recruiting |
| The First Affiliated Hospital of Henan University of Science and Technology | Henan, China | Recruiting |
| Huashan Hospital, Fudan University | Shanghai, China | Recruiting |
| West China Hospital, Sichuan University | Sichuan, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, China | Recruiting |
| The Second Affiliated Hospital, Zhejiang University School of Medicine | Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07551804